UCB S.A.
Strong FundamentalsStrong FundamentalsRevenue growing 59% YoY at strong marginsQuiet on X (1 mention/wk)$127.39-0.9%
Mentions · last 7 days
1
Price updated 1m ago·X counts updated 3d ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $UCBJY, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $UCBJY.
Biotechnology
No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.
Top industry ETF
$IBBiShares Biotechnology ETF
+12.0%YTD
+40.4%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
19.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
14.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
31.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
4.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
5.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
19.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
76.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$3.93$2.91+35.1%
Q4 2025Feb 26, 2026$3.79$2.91+30.2%
Q2 2025Jul 31, 2025$1.44$1.93-25.4%
Q4 2024Feb 27, 2025$4.56$1.35+237.8%
Next earningsThu, Feb 25·consensus EPS $3.13
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$4.2B+58.6%71.9%30.3%$2.83$1.4B
Q2 FY25$3.5B+34.7%73.6%19.2%$1.25$593.0M
Q4 FY24$3.4B+29.7%73.2%29.8%$2.26$659.0M
Q2 FY24$2.8B-4.6%69.5%11.6%$0.53$261.0M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$8.4B$8.2B – $8.7B$5.36$5.15 – $5.468
FY27$9.5B$9.2B – $9.8B$6.69$6.53 – $6.868
FY28$10.6B$10.3B – $11.0B$8.28$8.02 – $8.686
FY29$11.7B$11.5B – $12.2B$10.21$9.90 – $10.717
FY30$12.6B$12.3B – $13.1B$11.74$11.38 – $12.317
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.4.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.36%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-10.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-11.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 119.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $UCBJY on X in the last 7 days.